CJC-1295 No DAC + Ipamorelin 10mg

CJC-1295 No DAC + Ipamorelin 10mg — Dual GHRH/GHRP Research Blend

This combination formulation pairs two complementary growth hormone secretagogues — CJC-1295 No DAC (Modified GRF 1-29), a GHRH analogue, and Ipamorelin, a selective GHRP — into a single research compound studied for synergistic stimulation of pulsatile growth hormone release.

Unlike CJC-1295 DAC, the No DAC variant has a short half-life (~30 minutes), closely mimicking the natural GH release pattern. Combined with Ipamorelin’s selective ghrelin receptor agonism, this pairing is one of the most widely referenced dual-peptide protocols in GH secretagogue research.

Supplied as a lyophilised solid at ≥99% purity, UK-dispatched by OL Research. For laboratory and in-vitro research use only.

Key Research Areas

• Synergistic GH secretion — CJC-1295 No DAC activates GHRH receptors on pituitary somatotrophs while Ipamorelin simultaneously activates GHS-R1a (ghrelin receptor), producing significantly amplified GH pulse magnitude vs either compound alone
• Pulsatile release preservation — The short half-life of the No DAC variant maintains physiological GH pulsatility, a key variable in studies comparing natural vs sustained GH secretion patterns
• Selectivity profile — Ipamorelin is studied for its minimal effect on cortisol and prolactin secretion compared to other GHRPs (GHRP-2, GHRP-6), making it a preferred compound in selective GH pathway research
• IGF-1 pathway studies — Both compounds are investigated for downstream IGF-1 signalling in cell culture and animal models
• Body composition research — Referenced in studies on muscle protein synthesis and adipose tissue metabolism in laboratory models
• Sleep architecture studies — GH secretagogues including Ipamorelin have been investigated in models of nocturnal GH pulsatility and slow-wave sleep

Product Specifications

Understanding the Combination

CJC-1295 No DAC is a 29-amino acid analogue of endogenous growth hormone-releasing hormone (GHRH 1-29). The “No DAC” designation distinguishes it from CJC-1295 with Drug Affinity Complex, which extends half-life to ~8 days via albumin binding. The No DAC version retains the short, sharp GH pulse profile that mirrors endogenous secretion — making it the preferred variant in studies where maintaining natural pulsatility is the experimental variable.

Ipamorelin is a pentapeptide GHRP with high selectivity for the GHS-R1a receptor. Relative to earlier GHRPs, it is notable in research for its clean selectivity — stimulating GH release with minimal co-stimulation of ACTH, cortisol, or prolactin. This makes it a useful tool for isolating GH-specific effects in multi-variable research protocols.

The two mechanisms are complementary rather than redundant: GHRH analogues prime the pituitary for GH release while GHRPs trigger the release signal. Research consistently demonstrates that combined administration produces GH pulse amplitudes significantly greater than either compound alone — a core reason this pairing dominates the published GH secretagogue literature.

Frequently Asked Questions

What is the difference between CJC-1295 No DAC and CJC-1295 DAC?
The DAC (Drug Affinity Complex) modification extends half-life to approximately 8 days via albumin binding, creating sustained GH elevation. The No DAC version has a ~30-minute half-life, producing sharp GH pulses that mirror natural secretion. Research protocols requiring pulsatile GH typically use No DAC; those studying sustained GH elevation use DAC.

Why is Ipamorelin preferred over GHRP-2 or GHRP-6 in research?
Ipamorelin exhibits greater selectivity — it stimulates GH release with minimal impact on cortisol, prolactin, or ACTH secretion. GHRP-2 and GHRP-6 both produce stronger co-stimulation of these hormones, which complicates studies attempting to isolate pure GH pathway effects.

What purity standard is supplied?
≥99% for both compounds, verified by HPLC. Certificate of analysis available on request.

How should it be stored?
Refrigerated at 2–8°C in lyophilised form. Stable for 12+ months under proper conditions. Reconstituted solution should be stored at -20°C; minimise freeze-thaw cycles.

Is this product for human use?
No. Supplied strictly for in-vitro and laboratory research. Not a medicine, supplement, or food product.

Related Research Compounds

• CJC-1295 DAC 5mg — Extended half-life GHRH analogue for sustained GH elevation studies
• Ipamorelin 10mg — Standalone GHRP for isolated GHS-R1a research
• TB-500 10mg — Thymosin Beta-4 cellular repair and migration research
• MOTS-C 10mg — Mitochondrial and metabolic pathway research

Key Research References

• Ionescu M, Frohman LA (2006) — Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology & Metabolism
• Raun K et al. (1998) — Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology
• Bowers CY (1998) — Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences

⚠️ For laboratory and in-vitro research use only. Not for human consumption, veterinary use, or any clinical application. OL Research products are supplied in compliance with UK regulations governing research compounds.